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between pre- and postoperative measurements (p < 0.05). 
Subconjunctival reflux was recorded in 11.3%, and in this 
subgroup the IOP at 5 min and at 1 h was lower than preop-
erative IOP (p < 0.05).  Conclusions: More than one third of 
the eyes achieved IOPs >30 mm Hg 5 min after injection. 
Subconjunctival reflux contributed to a lower mean postop-
erative IOP (p < 0.05). Considerations for the management 
include prophylactic IOP lowering with medical therapy 
and/or preinjection ocular decompression for patients with 
a history of glaucoma or ocular hypertension and switching 
to an as-needed injection protocol in patients suffering a 
marked IOP rise in previous injections. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Intravitreal antivascular endothelial growth factor 
(anti-VEGF) agents are currently used for the treatment 
of neovascular age-related macular degeneration (AMD), 
diabetic retinopathy and retinal vein occlusion.
 Although ranibizumab is the licensed drug for intra-
vitreal treatment of neovascular AMD, bevacizumab has 
been widely used as an off-label treatment because of its 
lower cost  [1] .
 Key Words 
 Intraocular pressure · Risk factors · Intravitreal injection · 
Antivascular endothelial growth factor  
 Abstract 
 Purpose: The aim of the this study was to determine the ef-
fect of intravitreal antivascular endothelial growth factor in-
jections on intraocular pressure (IOP) and identify possible 
risk factors for the development of increased IOP.  Materials 
and Methods: This prospective study included a total of 106 
eyes receiving intravitreal injection of bevacizumab as treat-
ment for macular edema or active choroidal neovasculariza-
tion. IOP was measured by Goldmann applanation tonom-
etry immediately before the intravitreal injection and 5 min, 
1 h and 15 days after the procedure. The records of the study 
patients were reviewed for age, gender, history of glaucoma, 
diabetes mellitus, phakic status, systemic and topical medi-
cation and number of previous injections. Subconjunctival 
reflux was registered. IOP elevation was defined as IOP  ≥ 21 
mm Hg and/or a change from baseline of  ≥ 5 mm Hg record-
ed at least on two or more measurements on the same visit. 
 Results: Mean preoperative IOP was 15.31 ± 3.90 mm Hg and 
postoperative IOP values were 27.27 ± 11.87 mm Hg (after 5 
min), 17.59 ± 6.24 mm Hg (after 1 h) and 16.86 ± 3.62 mm Hg 
(after 15 days). The IOP variation was statistically significant 
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 The CATT study reported a very low rate of ocular 
complications, such as endophthalmitis, uveitis, retinal 
detachment or tear, vitreous hemorrhage and retinal vas-
cular events (all <1%)  [2] . That study, however, did not 
address the issue of intraocular pressure (IOP) elevation 
following repeated intravitreal anti-VEGF injections, 
which has previously been described with a prevalence 
between 2.9%  [3] , 11%  [1] and 27.6%  [4] .
 The MARINA and ANCHOR trials both found tran-
sient increases in IOP after injection in the respective 
treatment groups, but with very few patients experiencing 
a rise of  ≥ 40 mm Hg. However, the injection protocol did 
not mandate IOP measurement within 1 h of injection, 
and thus an IOP rise during this time frame was not re-
ported  [5–7] .
 Good et al.  [8] reviewed the charts of 215 eyes receiv-
ing one or more bevacizumab and/or ranibizumab injec-
tions for exudative AMD (101 eyes with bevacizumab). 
About 6% of the eyes experienced sustained IOP eleva-
tion and required medical or surgical therapy. This rate 
was significantly higher in patients with a history of pre-
existing glaucoma than in those without a glaucoma his-
tory (33 vs. 3.1%; p < 0.001). When comparing the fre-
quency of injections and the total number of injections 
received between the group experiencing sustained IOP 
rise and those that remained ocular normotensive, no dif-
ference was found  [8] .
 Other series investigating short-term IOP changes also 
found that IOP tended to return to a safe level in the ma-
jority of patients by 10–30 min following injection but did 
not investigate immediate postinjection IOP  [5] .
 In order to investigate the immediate short-term ef-
fects of anti-VEGF injection on IOP, Gismondi et al.  [9] 
 performed a prospective study of 54 eyes with intravit-
real ranibizumab. In that study, the IOP was measured 
immediately before as well as 5 s and 5, 10, 15, 30 and 60 
min and 1 day after injection. They found a considerable 
increase in IOP within 30 min of intravitreal injection. 
The difference between the IOP before and that after in-
jection was statistically significant after 5 s as well as after 
5, 10, 15 and 30 min (p = 0.0001); however, it was not sig-
nificant after 1 h (p = 0.064) and after 1 day (p = 0.449). 
About 90% of the study participants experienced an IOP 
rise of >30 mm Hg at 5 s after injection  [9] .
 A retrospective series performed by Kim et al.  [10] re-
vealed similar findings in 120 eyes of 112 patients receiv-
ing intravitreal injections of ranibizumab, bevacizumab, 
pegaptanib and triamcinolone acetonide. The mean IOP 
immediately after injection was 44 mm Hg (range 4–87), 
with 36% of the eyes experiencing a rise to  ≥ 50 mm Hg. 
Although the IOP was reduced to <30 mm Hg in 96% of 
the eyes by 15 min, the eyes with a history of glaucoma 
took significantly longer to reach this level (p = 0.002) 
 [10] .
 Short-term increases in IOP occurring after intravit-
real anti-VEGF injection therapy may take longer to nor-
malize in patients with preexisting glaucoma or ocular 
hypertension  [5] .
 The pathogenesis of short-term IOP elevation after an-
ti-VEGF injection most directly relates to an increase in 
intraocular fluid volume  [3–5, 10, 11] . Other potential 
variables influencing IOP rise include axial length, scleral 
thickness, scleral rigidity and ocular outflow facility  [5] . 
The pathogenesis of sustained elevation of intraocular 
pressure after intravitreal injections remains unknown. 
Several theories have been proposed, including a perma-
nent decrease in outflow facility due to repeated IOP 
spikes with each injection and subsequent damage to the 
trabecular meshwork, direct pharmacological toxicity 
and chronic trabeculitis  [5] .
 The acute increase in IOP is associated with a de-
creased papillary and juxtapapillary blood supply  [12] . 
Thus, an IOP elevation after intravitreal injection could 
result in damage of ganglion cells, which, if not identified 
and treated, can cause permanent visual loss, explaining 
the clinical importance of this study.
 The aim of this study was to determine the effect of 
intravitreal anti-VEGF injections on IOP 5 min, 1 h and 
15 days after the procedure and to investigate possible 
risks factors associated with elevated IOP. 
 Materials and Methods 
 This prospective study included 106 eyes of 79 patients treated 
with intravitreal bevacizumab (1.25 mg/0.05 ml) in an operating 
room of the Centro Hospitalar de Lisboa Central by 3 retina spe-
cialists between March 1 and August 31, 2013. 
 Eyes were included if IOP measurements were recorded imme-
diately before the intravitreal injection and 5 min, 1 h and 15 days 
after the procedure. Patients were excluded if they had a history of 
previous ocular surgeries (other than phacoemulsification), were 
aged <18 years, received topical corticosteroids, had had an intra-
vitreal injection of corticosteroids in the last 6 months, had ante-
rior chamber paracentesis or were administered prophylactic an-
tiglaucomatous drops on the perioperative period. Informed con-
sent was obtained from each patient. 
 Patients were uniformly sterilely prepped, which included a 
topical antibiotic (fourth-generation fluoroquinolone) as well as 
instillation of topical anesthesia using oxybuprocaine (4 mg/ml), 
insertion of a lid speculum and a 5% povidone iodine flush, fol-
lowed by a rinse with balanced salt solution. Injections of 0.05 ml 
of bevacizumab (1.25 mg/0.05 ml) were done using a superotem-
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poral (76 eyes) or infratemporal (30 eyes) approach at a distance of 
3.5–4.0 mm away from the limbus with a 30-gauge needle. After 
this procedure, the injection site was occluded temporarily and 
massaged with a sterile cotton-tipped applicator as the needle was 
withdrawn from the eye. Subconjunctival reflux was recorded. Ad-
ditional instillation of 5% povidone iodine and fourth-generation 
fluoroquinolone drops was performed. No anterior chamber punc-
ture was done after the injection. After each injection, the patients 
were instructed to use antibiotic drops 4 times daily for 5 days.
 IOP measurement was performed with a Goldmann tonometer 
by an ophthalmologist and was obtained at the beginning of the 
treatment before the first injection (baseline IOP) and 5 min, 1 h 
and 15 days after the injection. The tonometer prism was disin-
fected with 0.5% hypochlorite for 10 min before each measure-
ment.
 IOP elevation was defined as an IOP >21 mm Hg recorded on 
two measurements at the same visit to confirm the value, and if the 
difference between the measurements was >2 mm Hg, another 
ophthalmologist measured a third time so we could avoid a mea-
surement error. IOP elevation was also defined as a change from 
baseline of  ≥ 5 mm Hg. 
 Patients were classified as having glaucoma based on optic disk 
damage and visual field defect. All these glaucoma patients had 
previously been under antiglaucoma medication. Patient data that 
were collected included age, gender, history of glaucoma and dia-
betes, systemic and topical medication, phakic status, subconjunc-
tival reflux and total number of injections. A total of 30 eyes of 22 
patients did not attend to the visit 15 days after the injection.
 Statistical Analysis 
 Data analysis was performed using the software Statistical 
Package for the Social Sciences (SPSS) version 20.0 for Windows. 
The t test for paired samples was performed to compare the IOP 
before injection with the IOP 5 min, 1 h and 15 days after treat-
ment.
 Analysis of subconjunctival reflux occurrence, glaucoma, dia-
betes and phakic status and its relation with increased IOP 5 min, 
1 h and 15 days after the injection was performed with the t test for 
independent samples. The assumptions of these tests, including 
the assumption of normality of distribution and the assumption of 
homogeneity of variance, were analyzed with the Kolmogorov-
Smirnov and Levene’s test. When these assumptions were not sat-
isfied, the t test was replaced by the Mann-Whitney test for inde-
pendent samples and by the Wilcoxon test for paired samples. In 
situations where the samples were >30, according to the central 
limit theorem, the normal distribution of values was accepted. The 
relation between the presence of subconjunctival reflux and glau-
coma, diabetes and phakic status was tested using Fisher’s exact 
test. The correlation between the number of previous injections 
and increased IOP 5 min, 1 h and 15 days after injection was stud-
ied using the Pearson correlation coefficient. All p values were two-
sided, and statistical significance was defined as p < 0.05. 
 Results 
 A total of 106 consecutive eyes of 79 patients (60.4% 
females) who received  ≥ 1 intravitreal bevacizumab (1.25 
mg/0.05 ml) injections were included in this study. De-
mographics and baseline characteristics for all patients 
receiving bevacizumab injections are presented in  table 1 . 
The patients’ mean age was 70.61 ± 10.77 years (median 
72.50), 20.8% had a history of glaucoma and 60.8% of type 
2 diabetes, and 25.5% were pseudophakic. The mean 
number of total injections was 3.98 ± 3.06 (median 3).
 Diabetic retinopathy was the most frequent disease in 
our study ( fig. 1 ). IOP reached values  ≥ 30 mm Hg in 40 
eyes at 5 min following injection (37.8% of the sample) 
( fig. 2 ). IOP elevation occurred in 78.3% of the eyes at 5 
min, in 29.2% at 1 h and in 21.1% at 15 days following 
injection ( fig. 3 ).
 IOP values were significantly higher 5 min [27.27 vs. 
15.31 mm Hg, t(105) = –11.496; p = 0.001], 1 h [17.59 vs. 
15.31 mm Hg, t(105) = –4.829; p = 0.001] as well as 15 
days after injection [16.86 vs. 16.00 mm Hg, t(75) = 
–2,146; p = 0.035], although the sample size was smaller 
at this measurement ( table 2 ). 
 Table 1.  Demographics and baseline characteristics
Eyes, n 106
Age of the patients
Mean ± SD 70.61 ± 10.77
Range 35 – 91
Females 64 (60.4%)
Diabetes mellitus 64 (60.4%)
Glaucoma 22 (20.8%)
Phakic 79 (74.5%)
Pseudophakic 27 (25.5%)
Aphakic 0
Previous injections
Mean ± SD 3.93 ± 3.06
Range 1 – 18
DRP
AMD
RVO
Myopia
Uveitic
Idiopathic
1%1%3%10%
53%
32%
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Fig. 1. Disease rates. DRP = Diabetic retinopathy; RVO = retinal 
vein occlusion. 
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 Subconjunctival reflux occurred in 12 eyes, which rep-
resented 11.3% of the total study sample. The difference 
between IOPs before and 5 min after injection was sig-
nificantly lower in patients with reflux than in those 
without reflux (–2.81 vs. 13.67, Z = –5.237; p = 0.001). 
The same was found 1 h after injection [–3.54 vs. 2.95, 
t(104) = –4.576; p = 0.001]. However, there was no statis-
tically significant difference in IOP at 15 days between the 
two groups (–1.25 vs. 1.10; Z = –1.830; p = 0.067) ( ta-
ble 3 ). The subconjunctival reflux was more frequent in 
the superotemporal (11.8%) than in the inferotemporal 
(6.7%) approach.
 The difference between pre- and postinjection IOP 
was tendentiously higher in patients with glaucoma than 
in those without glaucoma at 5 min (12.90 vs. 11.71) and 
1 h (3.59 vs. 1.94) after injection [t(104) = 0.464; p = 0.644 
vs. t(24.329) = 1.018; p = 0.319, respectively]; 15 days after 
injection, this difference was greater in nonglaucomatous 
patients (1.16 vs. –0.031), although not statistically sig-
nificant [t(74) = –1.526; p = 0.272] ( table 4 ).
 Our sample showed a tendentiously higher increase in 
IOP at 5 min, 1 h and 15 days after injection in nondia-
betic than in diabetic patients [11.28 vs. 13.00, t(104) = 
–0.807; p = 0.422 vs. t(104) = –1.566; p = 0.120 vs. t(74) = 
–0.702; p = 0.912, respectively] ( table 5 ).
 The difference between the IOP before and 5 min, 1 h 
and 15 days after injection was tendentiously higher in 
phakic eyes than in pseudophakic eyes [12.16 vs. 11.74, 
t(103) = 0.177; p = 0.860; 2.33 vs. 2.25, t(103) = –0.068; 
p = 0.946; 0.89 vs. 0.78, t(73) = 0.111; p = 0.912, respec-
tively] ( table 6 ). 
 The Pearson correlation between the number of previ-
ous injections and increased IOP 5 min (r = 0.170, p = 
0.082), 1 h (r = 0.105, p = 0.285) and 15 days (r = 0.022, 
p = 0.853) after intravitreous injection was not statisti-
cally significant.
 Seventy-six eyes were injected into the superotempo-
ral quadrant and 30 eyes were injected into the infero-
temporal quadrant. In the superotemporal subgroup, at 
0
2
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 Fig. 2. IOP values after 5 min. 
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 Fig. 3. Mean IOP at each measurement. MD = Median. 
 Table 2. Mean IOP (mm Hg) before and after injection
Before injection  After injection p
After 5 min 0.001
Mean ± SD 15.31 ± 3.902 27.27 ± 11.87
Range 6 – 24 8 – 56
After 1 h 0.001
Mean ± SD 15.31 ± 3.902 17.59 ± 6.24
Range 6 – 24 6 – 36
After 15 days 0.035
Mean ± SD 16.00 ± 3.533 16.86 ± 3.62
Range 8 – 24 11 – 27
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the 5-min measurement, an IOP increase of 10.12 mm 
Hg from baseline was observed and the mean IOP was 
25.07 ± 10.79 mm Hg. Moreover, an IOP increase of 1.67 
mm Hg was found 1 h after the injection and of 1.6 mm 
Hg 15 days after the injection. Using the inferotemporal 
approach, the 5-min measurement showed an IOP in-
crease of 16.64 mm Hg from baseline and the mean IOP 
was 32.87 ± 12.81 mm Hg. Additionally, an IOP increase 
of 3.84 mm Hg was found 1 h after the injection and of 
1.18 mm Hg 15 days after the injection. This change in 
IOP was statistically significant between all pre- and 
postinjection measurements (5 min, 1 h and 15 days; p < 
0.05) using the superotemporal and inferotemporal ap-
proach. Subconjunctival reflux occurred in 11.8% of the 
superotemporal and in 6.7% of the inferotemporal sub-
group. 
 The study of the probability of subconjunctival reflux 
occurrence and its relation with possible risk factors, 
including glaucoma (OR = 2.444; 95% CI = 0.646–9.255; 
p = 0.234), diabetes (OR = 0.508; 95% CI = 0.145–1.787; 
p = 0.338) and phakic status (OR = 3.824; 95% CI = 0.466–
31.371; p = 0.282), revealed that none of these risk factors 
showed statistical significance (p > 0.05).
 Table 3. IOP (mm Hg) and subconjunctival reflux
Reflux No reflux p
Mean IOP ± SD before vs. after 5 min –2.81 ± 3.06 13.67 ± 9.93 0.001
Mean IOP ± SD before vs. after 1 h –3.54 ± 3.32 2.95 ± 4.56 0.001
Mean IOP ± SD before vs. after 15 days –1.25 ± 2.31 1.10 ± 3.51 0.067
 Table 4. IOP (mm Hg) and glaucoma
Glaucoma No
glaucoma
p
Mean IOP ± SD before vs. after 5 min 12.90 ± 12.03 11.71 ± 10.40 0.644
Mean IOP ± SD before vs. after 1 h 3.59 ± 7.32 1.94 ± 3.97 0.319
Mean IOP ± SD before vs. after 15 days –0.31 ± 5.00 1.16 ± 2.91 0.272
 Table 5. IOP (mm Hg) and diabetes mellitus
Diabetes No
Diabetes
p
Mean IOP ± SD before vs. after 5 min 11.28 ± 10.46 13.00 ± 11.12 0.422
Mean IOP ± SD before vs. after 1 h 1.68 ± 4.65 3.19 ± 5.10 0.120
Mean IOP ± SD before vs. after 15 days 0.62 ± 3.79 1.19 ± 2.97 0.485
 Table 6.  IOP (mm Hg) and phakic status
Phakic Pseudophakic p
Mean IOP ± SD before vs. after 5 min 12.16 ± 11.06 11.74 ± 9.84 0.860
Mean IOP ± SD before vs. after 1 h 2.33 ± 5.05 2.25 ± 4.43 0.946
Mean IOP ± SD before vs. after 15 days 0.89 ± 3.29 0.78 ± 4.13 0.912
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 Discussion and Conclusion 
 The use of intravitreal antiangiogenic agents has as-
sumed increasing importance and worldwide application 
in various vitreoretinal pathologies. Recent evidence sug-
gests that both short-term and sustained IOP increases 
associated with anti-VEGF intravitreal injection therapy 
are of a real clinical concern  [13] .
 In our study, at the 5-min measurement, an IOP in-
crease of 11.96 mm Hg from baseline was observed and 
the mean IOP was 27.27 mm Hg (range between 8 and 56 
mm Hg). An IOP increase of 2.28 mm Hg was found 1 h 
after the injection and of 1.55 mm Hg 15 days after the 
injection. This change in IOP was statistically significant 
between all pre- and postinjection measurements (5 min, 
1 h and 15 days; p < 0.05). 
 IOP reached levels  ≥ 30 mm Hg in more than one third 
of the patients (37.8%) within 5 min after intravitreous 
injection of bevacizumab. This pressure could affect the 
optic nerve by different pathophysiological mechanisms 
(mechanical direct effect and changes in perfusion pres-
sure). Studies like those by Hollands et al.  [3] and Kim et 
al.  [10] also describe pressure peaks in the short-term 
postinjection period, which corroborates the fact that this 
increase in IOP can be transitory. 
 In any case, there is recent evidence suggesting that 
both IOP increases (short-term and persistent) related to 
intravitreous injections require a medical approach. 
Treating physicians should be aware of this infrequent 
complication and manage these occurrences appropri-
ately.  
 Current evidence suggests that otherwise healthy eyes 
can tolerate a short-term IOP rise with no permanent ef-
fects on visual function  [14] . However, the effects of these 
IOP spikes pose a real threat to the health of the optic 
nerve in individuals with advanced glaucomatous optic 
neuropathy. Prior studies have demonstrated clear visual 
field progression  [15] and even loss of fixation  [16] asso-
ciated with short-term IOP spikes following cataract sur-
gery.
 Considerations for management include prophylactic 
IOP lowering with medicinal therapy and/or preinjection 
ocular decompression for patients with a history of glau-
coma or ocular hypertension and switching to an as-
needed injection protocol in patients suffering a sus-
tained IOP rise  [5] . However, according to El Chehab et 
al.  [17] , the administration of oral acetazolamide is inef-
fective in preventing these IOP peaks. 
 Another result that was achieved with statistical sig-
nificance in our study was the occurrence of subconjunc-
tival reflux in 11.3% of eyes, which contributes to a small-
er increase in IOP after injection when compared with 
patients who did not suffer a reflux (p < 0.05). In other 
studies, the subconjunctival reflux occurred in between 
17  [18] and 38%  [19] of the eyes. The presence of a sub-
conjunctival reflux depended on the intravitreal injection 
technique (in order of decreasing reflux rate: straight, 
oblique and double-plane tunnel scleral  [20] ) and on the 
diameter of the needle (30 G causes less reflux than 27 G, 
particularly when the injection is not beveled  [21] ). Since 
the injected dose and volume of the drug as well as the 
injection technique and needle diameter were the same in 
all cases, it is unlikely that these variables were the cause 
of the IOP elevation. One of the limitations of this study 
is the qualitative evaluation of the subconjunctival reflux 
instead of a quantitative one.
 None of the studied parameters, including diabetes 
mellitus, glaucoma, injection site (supero/inferotempo-
ral) and number of injections, were statistically signifi-
cant in this sample. The small sample of glaucoma pa-
tients (20.8%) and the no-show of 30 patients 15 days af-
ter the injection may have an impact on these results. 
 While more injections could be expected to lead to a 
direct toxic effect on aqueous outflow, causing chronic 
inflammation or trabeculitis, there was no evidence of an-
terior segment inflammation or synechiae in any of the 
eyes in this series. Moreover, no significant associations 
between increased IOP and mean number of injections 
were observed, leading us to conclude that this factor can-
not be implicated as being causative for the elevated IOP 
in our study. This is in agreement with Good et al.  [8] and 
Mathalone et al.  [1] who also did not find the number of 
injections to be a risk factor for IOP elevation.
 The relationship between the presence of subconjunc-
tival reflux and potential risk factors was not statistically 
significant, which is in agreement with other studies  [22] . 
However, the small number of reflux episodes may have 
influenced these results.
 In conclusion, intravitreal injection of bevacizumab led 
to an IOP increase of about 14 mm Hg 5 min after the in-
jection, in the absence of subconjunctival reflux. This IOP 
increase, although lower, was also observed at 15 days in-
dicating that these eyes may be targets of optic nerve dam-
age beyond the immediate postinjection period. For this 
reason, the authors of this study recommend the imple-
mentation of the aforementioned measures of prevention, 
especially in patients with a history of glaucoma or ocular 
hypertension, and switching to an as-needed injection 
protocol (the eyes should be injected in the presence of 
choroidal neovascularization activity: subretinal/intraret-
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inal activity, loss of >5 letters in the best visual acuity or 
persistent/recurrent retinal hemorrhage) in patients who 
have suffered a marked rise in IOP in previous injections. 
The safety and efficacy of a flexible dosing regimen of ra-
nibizumab in neovascular age-related macular degenera-
tion (SUSTAIN study) revealed similar results in a phase 
III, multicenter trial in which patients were retreated with 
injection therapy based on prespecified criteria, termed as 
the ‘as-needed’ or ‘pro re nata’ protocol  [23] .
 An IOP increase due to an increase in intraocular vol-
ume subsequent to an intravitreal injection is inevitably 
linked to the elasticity of both ocular tissues. One way to 
study this in the clinical setting is by using a dynamic con-
tour tonometer and through ocular pulse amplitude anal-
ysis. This variable reflects not only the amplitude in cho-
roidal flow during a cardiac cycle, but can also give an 
indirect insight into the ocular compliance. As the sub-
stances injected in this study (anti-VEGF) may have an 
effect on ocular blood flow, ocular pulse amplitude is a 
particularly suitable parameter for future research in this 
field of study  [24, 25] .
 Prospective studies with complementary diagnosis ex-
ams of the retinal ganglion cell layer are also needed to 
investigate and document this possibly irreversible dam-
age to the optic nerve.
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